Please use this identifier to cite or link to this item: http://dspace.nuph.edu.ua/handle/123456789/26717
Title: Comparison of components profile in herbal raw material, extract and pharmaceuticals of hedera helix
Authors: Bezruk, I.
Georgiyants, V.
Ivanauskas, L.
Keywords: ivy leaf;components profile;pharmaceuticals;extracts;HPLC
Issue Date: 2020
Bibliographic description (Ukraine): Bezruk, I. Comparison of components profile in herbal raw material, extract and pharmaceuticals of hedera helix / I. Bezruk, V. Georgiyants, L. Ivanauskas // ScienceRise: Pharmaceutical Science. - 2020. - № 26 (4). - P. 36-39. doi : https://doi.org/10.15587/2519-4852.2020.210768
Abstract: The aim. To investigate both the profile of components and possible difference among herbal raw materials, semi-products and pharmaceuticals of Hedera helix for determination of main standartisation markers.Materials and methods. Investigation of components profile has been performed using the Shimadzu Nexera X2 chromatographic system coupled with a diode-areadetector. The ACE C 18 column (250 mm×4.6 mm with particle size 5 m) was used for the separation of components. 0.1 % acetic acid and acetonitrile were used as mobile phase A and B, respectively. Studies have been performed on the leaves, dry extract andcap-sules of H. helix.Results. The determined profile had no significant variation among samples. It has been presented by 19 various components, such as phenolic acids, flavonoids and triterpene saponins. However, kaempferol, nicotiflorin and t-cinnamic acid were not found in the leaf raw material. Hederacoside C might be highlighted as the main mark-er of raw materials and products of H. helix due to its significant amount in comparison to other components. Its amount was in the range of 64,80 % up to 71,46 % of the total content of components. Moreover, according to some pharmacological studies, hederacoside C is responsible for pharmaceutical usage of H. helix pharmaceu-tics. Nevertheless, it is not recommended to standardize the plant-based medicines by one marker, since the pharmaceutical activity of such dosage forms is defined by synergism action of all constituents. Except for hede-racoside C significant amounts in comparison to other components were found for chlorogenic acid and 4,5-dicaffeoylquinic acid about 5 % and 3 % respectively. Though the latter was found in small concentrations in leaves (0,058 %). This sample had a much higher amount of 3,5-dicaffeoylquinic acid, but in the case of extract and capsules, its content was lower 1,55 % and 0,66 % respectively. Thus, chlorogenic acid has been chosen as a second marker due to its high concentration in all samples and some pharmaceutical activities, such as antiox-idant and anti-inflammatory effects.Conclusions. It was found, that standartisation ofH. helix products is preferably to perform with determination both hederacoside C and chlorogenic acid. These components were dominant among all components; besides they possess a wide range of pharmaceutical effects. Hence, quantification of hederacosideC and chlorogenic acid is necessary to ensure the high quality of H. helix pharmaceuticals.
URI: http://dspace.nuph.edu.ua/handle/123456789/26717
Appears in Collections:Наукові публікації кафедри фармацевтичної хімії



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.